Prostate Cancer
Conditions
Keywords
Prostate cancer, testosterone, castration, degarelix, proliferation
Brief summary
The biological effects of castration on prostate cancers will be studies by administration of degarelix prior to radical prostatectomy. The effects will be studied by analysis of gene expression and immunohistochemistry focusing on markers of proliferation and apoptosis of samples taken at the time of radical prostatectomy (7 days after administration of degarelix). Tumours from patients treated with neo-adjuvant degarelix will be compared with tumours from patients who have not been medically castrated.
Interventions
DRUG240mg degarelix s.c. injection
7 days prior to radical prostatectomy the patient will have a subcutaneous injection of 240mg degarelix.
Sponsors
University of Cambridge
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Intermediate/high risk prostate cancer * Patient eligible for and wanting surgery
Exclusion criteria
* Inability to consent * Previous thromboembolism/arrhythmias * contraindication to degarelix or surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| proliferative index defined by immunohistochemistry for ki67 | at surgery, 7 days after administration of degarelix |
Secondary
| Measure | Time frame |
|---|---|
| Gene expression levels measured by microarray | At surgery 7 days after degarelix administration |
Countries
United Kingdom
Contacts
Primary ContactGreg Shaw, MBBS MD FRCS
Backup ContactMarie Corcoran
Outcome results
None listed